Allergan (AGN) Outpaces Stock Market Gains: What You Should Know

Allergan (AGN) closed the most recent trading day at $164, moving +1% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.03%. Elsewhere, the Dow gained 0.28%, while the tech-heavy Nasdaq lost 0.04%.

Prior to today's trading, shares of the Botox maker had gained 2.34% over the past month. This has outpaced the Medical sector's loss of 1.69% and the S&P 500's gain of 2.25% in that time.

Investors will be hoping for strength from AGN as it approaches its next earnings release. In that report, analysts expect AGN to post earnings of $4.21 per share. This would mark a year-over-year decline of 0.94%. Our most recent consensus estimate is calling for quarterly revenue of $3.85 billion, down 1.51% from the year-ago period.

For the full year, our Zacks Consensus Estimates are projecting earnings of $16.69 per share and revenue of $15.45 billion, which would represent changes of 0% and -2.14%, respectively, from the prior year.

Investors might also notice recent changes to analyst estimates for AGN. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.14% higher within the past month. AGN currently has a Zacks Rank of #3 (Hold).

Looking at its valuation, AGN is holding a Forward P/E ratio of 9.73. Its industry sports an average Forward P/E of 7.47, so we one might conclude that AGN is trading at a premium comparatively.

Meanwhile, AGN's PEG ratio is currently 1.68. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Generic Drugs was holding an average PEG ratio of 0.87 at yesterday's closing price.

The Medical - Generic Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 60, which puts it in the top 24% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Allergan plc (AGN): Free Stock Analysis Report
To read this article on click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.